Home › Trials › NCT05767307
Clinical trial Recruiting at 1 site Observational Ages 18 to 99 Men only

New urine test for prostate cancer detection

Official title: Danish Prostate Cancer Consortium Study-1 (DPCC-1): Multicenter Development of Liquid Biopsy Biomarkers for Early Detection of Prostate Cancer.

Run by University of Aarhus · NCT05767307 · Data updated 2026-11-12

This study is testing a new urine test called uCaP to see if it can better identify men who might need an MRI for prostate cancer compared to the standard PSA test.

Quick facts

Study typeObservational
Ages18 Years to 99 Years
SexMen only
Enrollment2500 (estimated)
SponsorUniversity of Aarhus
Academic / other
Locations3 sites (Aarhus N, Aarhus and 2 other locations)
StatusRecruiting
StartedAugust 1, 2022
Main results expectedDecember 31, 2025
Study endsJanuary 1, 2040
Registry record updatedNovember 29, 2023
Trial IDNCT05767307 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are men aged 18 and older who are referred for an MRI due to suspicion of prostate cancer and can understand Danish.

Probably not a fit

Patients who have previously been diagnosed with prostate cancer or other urogenital cancers will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates a new microRNA-based urine biomarker test, uCaP, to determine its effectiveness compared to the standard PSA test in identifying men who may need an MRI scan for prostate cancer. The study will enroll 2,500 men referred for MRI at three major hospitals in Denmark. The goal is to assess whether uCaP can improve the accuracy of identifying treatment-requiring prostate cancer, potentially reducing unnecessary procedures and overdiagnosis. By comparing the performance of uCaP against PSA, the study aims to enhance early detection of aggressive prostate cancer while minimizing overtreatment of indolent cases.

Why it matters

Potential benefit: If successful, this test could lead to more accurate prostate cancer diagnoses and reduce unnecessary medical interventions.

How similar studies have gone: Other studies have shown promise in using biomarker tests for cancer detection, but this specific approach with uCaP is novel.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Age ≥ 18 years.
* Understand oral and written Danish.
* Referred to MRI (multi or bi-parametric) due to suspicion of PC at AUH, OUH, or HGH.

Exclusion Criteria:

* Previously diagnosed with PC or other urogenital cancers.
* Has one or more contraindications for MRI.
* Have had gender reassignment treatment.
* Blood PSA levels \> 20 μg/l.

Where it's running

  • Aarhus University Hospital
    Aarhus N, Aarhus, Denmark     Recruiting
  • Herlev & Gentofte University Hospital
    Hellerup, Denmark     Not yet recruiting
  • Odense University Hospital
    Odense, Denmark     Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Prostate Cancer 1464University of Aarhus 153
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.